Treatment for severe COVID-19 with a biomimetic sorbent haemoperfusion device in patients on haemodialysis

Haemodialysis (HD) patients present more morbidity and mortality risk in coronavirus disease 2019 (COVID-19). In patients who may develop severe symptoms, the process called ‘viral sepsis’ seems to be a crucial mechanism. In those cases, the HD procedure provides an excellent tool to explore the ben...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandoval, Diego, Rama, Inés, Quero, María, Hueso, Miguel, Gómez, Francisco, Cruzado, Josep M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Exceptional Cases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7929023/
https://www.ncbi.nlm.nih.gov/pubmed/33953913
http://dx.doi.org/10.1093/ckj/sfab010
_version_ 1783659912993177600
author Sandoval, Diego
Rama, Inés
Quero, María
Hueso, Miguel
Gómez, Francisco
Cruzado, Josep M
author_facet Sandoval, Diego
Rama, Inés
Quero, María
Hueso, Miguel
Gómez, Francisco
Cruzado, Josep M
author_sort Sandoval, Diego
collection PubMed
description Haemodialysis (HD) patients present more morbidity and mortality risk in coronavirus disease 2019 (COVID-19). In patients who may develop severe symptoms, the process called ‘viral sepsis’ seems to be a crucial mechanism. In those cases, the HD procedure provides an excellent tool to explore the benefit of some extracorporeal therapies. We reported the outcome of four HD patients with severe COVID-19 treated with Seraph(®)100 haemoperfusion (HP) device. Three of the four cases presented a good clinical response after HP. In conclusion, the treatment with Seraph(®)100 device may be a simultaneous treatment to improve HD patients with severe acute respiratory syndrome coronavirus 2.
format Online
Article
Text
id pubmed-7929023
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-79290232021-03-04 Treatment for severe COVID-19 with a biomimetic sorbent haemoperfusion device in patients on haemodialysis Sandoval, Diego Rama, Inés Quero, María Hueso, Miguel Gómez, Francisco Cruzado, Josep M Clin Kidney J Exceptional Cases Haemodialysis (HD) patients present more morbidity and mortality risk in coronavirus disease 2019 (COVID-19). In patients who may develop severe symptoms, the process called ‘viral sepsis’ seems to be a crucial mechanism. In those cases, the HD procedure provides an excellent tool to explore the benefit of some extracorporeal therapies. We reported the outcome of four HD patients with severe COVID-19 treated with Seraph(®)100 haemoperfusion (HP) device. Three of the four cases presented a good clinical response after HP. In conclusion, the treatment with Seraph(®)100 device may be a simultaneous treatment to improve HD patients with severe acute respiratory syndrome coronavirus 2. Oxford University Press 2021-01-18 /pmc/articles/PMC7929023/ /pubmed/33953913 http://dx.doi.org/10.1093/ckj/sfab010 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of ERA-EDTA. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Exceptional Cases
Sandoval, Diego
Rama, Inés
Quero, María
Hueso, Miguel
Gómez, Francisco
Cruzado, Josep M
Treatment for severe COVID-19 with a biomimetic sorbent haemoperfusion device in patients on haemodialysis
title Treatment for severe COVID-19 with a biomimetic sorbent haemoperfusion device in patients on haemodialysis
title_full Treatment for severe COVID-19 with a biomimetic sorbent haemoperfusion device in patients on haemodialysis
title_fullStr Treatment for severe COVID-19 with a biomimetic sorbent haemoperfusion device in patients on haemodialysis
title_full_unstemmed Treatment for severe COVID-19 with a biomimetic sorbent haemoperfusion device in patients on haemodialysis
title_short Treatment for severe COVID-19 with a biomimetic sorbent haemoperfusion device in patients on haemodialysis
title_sort treatment for severe covid-19 with a biomimetic sorbent haemoperfusion device in patients on haemodialysis
topic Exceptional Cases
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7929023/
https://www.ncbi.nlm.nih.gov/pubmed/33953913
http://dx.doi.org/10.1093/ckj/sfab010
work_keys_str_mv AT sandovaldiego treatmentforseverecovid19withabiomimeticsorbenthaemoperfusiondeviceinpatientsonhaemodialysis
AT ramaines treatmentforseverecovid19withabiomimeticsorbenthaemoperfusiondeviceinpatientsonhaemodialysis
AT queromaria treatmentforseverecovid19withabiomimeticsorbenthaemoperfusiondeviceinpatientsonhaemodialysis
AT huesomiguel treatmentforseverecovid19withabiomimeticsorbenthaemoperfusiondeviceinpatientsonhaemodialysis
AT gomezfrancisco treatmentforseverecovid19withabiomimeticsorbenthaemoperfusiondeviceinpatientsonhaemodialysis
AT cruzadojosepm treatmentforseverecovid19withabiomimeticsorbenthaemoperfusiondeviceinpatientsonhaemodialysis

Ejemplares similares